Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Acromesomelic dysplasia, Maroteaux type 1

Interventions

Cyclophosphamide 7Etoposide 6fludarabine phosphate 5Methotrexate 5Filgrastim 5Vincristine 4Rituximab 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Antilymphocyte Serum 4Methylprednisolone 3Ifosfamide 3Doxorubicin 3Cytarabine 3Busulfan 3aldesleukin 2Vorinostat 2Prednisone 2Oxaliplatin 2Mycophenolic Acid 2Mercaptopurine 2Melphalan 2Dexamethasone 2Daunorubicin 2Cyclosporine 2Asparaginase 2trioctyl phosphine oxide 1sargramostim 1pevonedistat 1obatoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Dendritic Cell Sarcoma, Interdigitating × pevonedistat × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡